Document is current
Any future updates will be listed below
-
Authors
Sisca, L.
Polito, M. G.
Silletta, M.
La Cesa, A.
Scafetta, R.
Donato, M.
Gullotta, C. M.
Guarino, A.
Barnini, G.
Speziale, E.
Troiano, R.
Foderaro, S.
Iuliani, M.
Simonetti, S.
Cavalieri, S.
Calagna, S.
Cortellini, A.
Vincenzi, B.
Tonini, G.
Pantano, F.
- License Information
-
More Information
Article History
Received: 7 November 2025
Accepted: 2 February 2026
First Online: 23 February 2026
Declarations
:
: Giuseppe Tonini has served on advisory boards for Molteni, Novartis, PharmaMar, and MSD. Francesco Pantano has served on advisory boards for Lilly, Gilead, AstraZeneca, Novartis, and Daiichi Sankyo. Alessio Cortellini has received honoraria or consulting fees from Bristol-Myers Squibb, AstraZeneca, MSD Oncology, Regeneron, Amgen, Daiichi Sankyo/AstraZeneca, Roche, Access Infinity, Ardelis Health, Iqvia, Alpha Sight, Capvision, techspert.io, Atheneum, Alira Health, Tegus, and Johnson & Johnson/Janssen. All other authors declare no conflicts of interest. The declaration of interest form for Bruno Vincenzi is pending and will be provided upon request.
